Esperion Therapeutics ESPR 深 滬
等待開盤 12-12 09:30:00 美东时间
4.08
+0.250
+6.53%
華盛通- 最 高4.125
- 今 開3.84
- 成交量 1142.72万股
- 最 低 3.80
- 昨 收 3.83
- 總市值 9.47亿
- 52周最高 4.125
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6925
- 委 比 -92.07%
- 總股本 2.32亿
- 歷史最高 120.96
- 量 比 2.75
- 振 幅 8.49%
- 歷史最低 0.6925
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion granted new employees stock options and RSUs under its 2017 Inducement Plan. John Harlow, the new Chief Commercial Officer, received 380,000 stock options and 424,536 RSUs. The options have an exercise price of $3.79 per share, vesting 25% after one year and the remaining 75% in quarterly installments. The RSUs vest similarly. Esperion focuses on developing medicines for cardiovascular disease, supported by clinical data and advancing it...
12-09 21:30
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Piper Sandler Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $9
Piper Sandler analyst David Amsellem initiates coverage on Esperion Therapeutics (NASDAQ:ESPR) with a Overweight rating and announces Price Target of $9.
11-25 22:19
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Esperion announced that its Canadian partner, HLS Therapeutics, has received Health Canada approval to market NILEMDO and NEXLIZET for reducing LDL-Cholesterol in at-risk Canadians. This marks a significant milestone in Esperion's global strategy to expand access to its LDL-C lowering therapies. With cardiovascular disease affecting 2.6 million Canadians and being the second leading cause of death, the approval underscores the urgent need for eff...
11-18 12:00
Esperion Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Esperion Therapeutics shares are trading lower after the company reported worse...
11-07 00:57
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion granted 23 new employees 77,650 restricted stock units (RSUs) on November 4, 2025, under its 2017 Inducement Equity Incentive Plan designed to attract new hires. Each RSU vests 25% one year after employment starts, with the remaining 75% vesting in 12 quarterly installments. Esperion, a biopharmaceutical company, focuses on developing innovative cardiovascular disease treatments, including ATP citrate lyase inhibitors, and builds on its ...
11-06 21:30
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Snap Inc (NYSE:SNAP) rose sharply in pre-market trading after the com...
11-06 19:32
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
Esperion Therapeutics reported Q3 2025 total revenue of $87.3 million, up 69% Y/Y, driven by U.S. net product revenue growth of 31% to $40.7 million. The company reached a settlement agreement with Dr. Reddy's Laboratories to delay generic versions of NEXLETOL and NEXLIZET until 2040. Bempedoic acid received Level 1a recommendation in updated ESC/EAS guidelines. Partner Otsuka received regulatory approval for NEXLETOL in Japan, with favorable pri...
11-06 11:00
Esperion Appoints New Chief Commercial Officer
An announcement from Esperion ( ($ESPR) ) is now available. On November 4, 2025...
11-04 22:19
